SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Vertex Pharmaceuticals (CA): Phase 3 STRIVE Study of VX-770 Showed Durable Improvements in Lung Function (FEV1) and Other Measures of Disease Among People With a Specific Type of Cystic Fibrosis